A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC)
Phase: PHASE2
Conditions: Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
Sponsor: Kimberly Perez, MD

[cover page generated for ClinicalTrials.gov only. This page was not part of the IRB approved document  
which follows] 
 
Identifiers: NCT05546411 
Unique Protocol ID: 22-314  
Brief Title: A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer 
Full Title: A Phase 2 study of neoadjuvant NIS793 in Combination with mFOLFIRINOX in 
resectable and borderline resectable pancreatic adenocarcinoma (PDAC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date document downloaded from OncPro portal: 4.26.2024  
Document Date: Protocol Version: 03.13.2023